ALK Fusion Protein Expression
5 clinical trials · Condition
◉ Watch ALK Fusion Protein Expression
| Record | Firm | Date |
|---|---|---|
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer (NCT05186506) | Sichuan University | 2022-01-01 |
| Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (NCT04921553) | Centre Leon Berard | 2021-06-22 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers (NCT03868423) | Sameek Roychowdhury | 2019-03-20 |
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma (NCT02587650) | University of California, San Francisco | 2015-03-26 |
Track ALK Fusion Protein Expression automatically
Every clearance here is in the API, with alerts when new ones post.